The study, “Anti-Selig-8 Antibody for Eosinophilic Gastritis and Duodenitis” was presented by Evan Dellon, MD, a professor of medicine in the division of gastroenterology and hepatology at the University of North Carolina at Chapel Hill. The study looks at a potential therapeutic treatment for patients with eosinophilic gastrointestinal disorders and duodenitis.
The other study, “Integrating Global Health with the Microbiome,” was presented by Jeffrey Gordon, MD the Dr. Robert J. Glaser Distinguished University Professor at Washington University in St. Louis. The study examined and reclassified current understanding of gut physiology in children with stunted growth.
The Clinical Research Forum honors “groundbreaking clinical and translational research advances that benefit the health and welfare of all Americans,” according to a March 30 news release. Recipients of the award were chosen through nominations within the scientific community. Read the full list of recipients here.
More articles on surgery centers:
Feds eye $147M paid to ASC, clinic owner for uninsured COVID-19 patient treatment
ASCs return to growth: Big plans from innovative execs
15 ASCs opened or announced in March
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
